- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BMY
Recent news which mentions BMY
3 AI Stocks That Could Skyrocket Your Wealth
June 20, 2023
From InvestorPlace
3 Bargain Stocks to Buy on the Dip
June 17, 2023
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
June 16, 2023
From Benzinga
The stock market is in a bull market? What bull market?
June 13, 2023
From MarketWatch
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
June 12, 2023
From Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
June 06, 2023
From Benzinga
Chipotle, Bristol-Myers Squibb, Corteva And A Healthcare Giant On CNBC's 'Final Trades'
June 06, 2023
From Benzinga
From MarketWatch
Bristol Myers' Opdivo/Chemo Shows Durable Results At Four Years In Lung Cancer Patients
June 05, 2023
Tickers
BMY
From Benzinga
3 Dividend Stocks You Can Buy Without Any Hesitation
June 03, 2023
From Motley Fool
‘Millions of women suffering in silence’: Female workers want menopause benefits, so why are they so rare?
June 02, 2023
From MarketWatch
3 Top Stocks That Just Went on Sale
June 01, 2023
From Motley Fool
From Benzinga
Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients
May 26, 2023
Tickers
BMY
From Benzinga
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
May 25, 2023
From Benzinga
Quant Ratings Updated on 119 Stocks
May 23, 2023
From InvestorPlace
From Benzinga
From Benzinga
Pfizer CEO Fires Back On US Drug Pricing Reforms: 'Negotiation with a Gun to Your Head'
May 12, 2023
From Benzinga
From Motley Fool
Tickers
BMY
From Motley Fool
$100,000 Salaries No Longer Enough — Majority Living Paycheck To Paycheck With No Savings
May 09, 2023
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.